An earlier version of this story said Fleurish was pursuing a listing on the Canadian Securities Exchange via reverse takeover. The company says it no longer plans to pursue a public listing.
An Ottawa-area pot firm targeting the cannabis industry’s female consumers has secured a production licence from Health Canada.
Now certified, Fleurish Cannabis will begin cultivation of cannabis strains at its 20,000-square-foot facility in Kemptville. Roughly 75 per cent of the site will be dedicated to growing with the remainder acting as an R&D space for the firm.
At full capacity, the facility is expected to produce 1,400 kilograms of cannabis per year.
Fleurish will develop cannabis products such as dried flowers, pre-rolls and edible oils targeted at women in both the medical and recreational markets in Canada. Founder Renee Ellison told OBJ the firm’s surveys of female consumers revealed that women prefer different cannabis experiences such as topical ointments and other non-smokable options.
Chief marketing officer Mary Beth Williamson told OBJ earlier this year that Fleurish’s focus on women will help differentiate its offerings from larger incumbents.
“We are the only company exclusively targeting the health and wellness of women. When you’re unique, that is much more distinctive and stands out more,” she said.
Fleurish has raised roughly $7 million in private financing and was noted to be pursuing some 200,000 square feet of space for a larger cultivation facility, but Quinte News has reported the deal to secure such a site in Belleville has fallen through.